Windlas Biotech Ltd's Q3FY25 Quarter Results
- 12 Feb 2025
Result Summary
- Windlas Biotech Ltd reported a 3.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.4%.
- Its expenses for the quarter were up by 4.2% QoQ and 22.8% YoY.
- The net profit decreased 0.5% QoQ and increased 3.2% YoY.
- The earnings per share (EPS) of Windlas Biotech Ltd stood at 7.4 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 199.13 | 191.84 | 165.38 | 3.8% | 20.4% |
Total Expenses | 178.79 | 171.55 | 145.57 | 4.2% | 22.8% |
Profit Before Tax | 20.34 | 20.29 | 19.81 | 0.2% | 2.7% |
Tax | 4.76 | 4.63 | 4.71 | 2.8% | 1.1% |
Profit After Tax | 15.58 | 15.66 | 15.10 | -0.5% | 3.2% |
Earnings Per Share | 7.40 | 7.40 | 7.30 | 0.0% | 1.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Windlas Biotech Ltd is a well-recognized entity in the pharmaceutical industry, primarily engaged in the manufacturing and commercialization of pharmaceutical formulations. The company is known for its focus on contract development and manufacturing, catering to both domestic and international markets. Windlas Biotech's core offerings include a range of pharmaceutical products, such as oral solid and liquid formulations, which are distributed through various strategic partnerships. As of the latest reports, there are no significant developments or changes in the company's business model or operational strategy. The company continues to operate within the healthcare and pharmaceutical sector, providing essential healthcare solutions to its client base.
Revenue
In the third quarter of the fiscal year 2025, Windlas Biotech Ltd reported a total income of ₹199.13 crores, reflecting a 3.8% increase from the previous quarter's total income of ₹191.84 crores. This quarter-over-quarter growth is complemented by a substantial year-over-year increase of 20.4% compared to the total income of ₹165.38 crores recorded in the third quarter of the fiscal year 2024. The consistent rise in revenue highlights the company's ability to enhance its income streams, possibly through expanded operations or increased market penetration. The upward trajectory in revenue generation is a critical component of the company’s financial health, showcasing its ability to leverage its market position effectively.
Profitability
The profitability metrics for Windlas Biotech Ltd in Q3FY25 illustrate a stable financial performance. The company achieved a Profit Before Tax of ₹20.34 crores, marking a slight increase of 0.2% from the ₹20.29 crores in Q2FY25, and a 2.7% rise from ₹19.81 crores in Q3FY24. The Tax expense for the quarter stood at ₹4.76 crores, representing a 2.8% increase quarter-over-quarter and a marginal 1.1% increase year-over-year. Consequently, the Profit After Tax was ₹15.58 crores, slightly declining by 0.5% from the previous quarter's ₹15.66 crores, yet showing a 3.2% increase from the ₹15.10 crores reported in the same quarter last year. Earnings per share remained consistent at ₹7.40, unchanged from the previous quarter, yet reflecting a slight annual increase of 1.4% from ₹7.30 reported in Q3FY24.
Operating Metrics
The total expenses for Windlas Biotech Ltd in Q3FY25 amounted to ₹178.79 crores, demonstrating a 4.2% increase from Q2FY25's total expenses of ₹171.55 crores and a 22.8% increase from the ₹145.57 crores recorded in Q3FY24. This escalation in expenses is indicative of the company's ongoing operational activities and possibly increased production or expanded operations. Despite the rise in expenses, the company's profit metrics indicate effective cost management strategies that have allowed for sustained profitability. The consistency in the Earnings Per Share metric also reflects the company's ability to maintain shareholder value amidst fluctuating operational costs.
